

1 Molnupiravir clinical trial simulation suggests that polymerase chain
2 reaction underestimates antiviral potency against SARS-CoV-2

3
4
5 **Authors**

6 Shadisadat Esmaeili,^{1*} Katherine Owens,¹ Jessica Wagoner,² Stephen J. Polyak,² Shengyuan
7 Zhang³, Joseph F. Standing^{3,4}, David M. Lowe^{5,6}, Joshua T. Schiffer^{1,7}

8
9 **Affiliations**

10 ¹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA.

11 ² Department of Laboratory Medicine & Pathology, University of Washington; Seattle, WA, USA.

12 ³ Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University
13 College London, London, UK

14 ⁴ Great Ormond Street Hospital for Children NHS Trust, London, UK

15 ⁵ Department of Clinical Immunology, Royal Free London NHS Foundation Trust, London, UK.

16 ⁶ Institute of Immunity and Transplantation, University College London, London, UK

17 ⁷ Department of Medicine, University of Washington; Seattle, WA, USA.

18

19 *Corresponding Author: sesmaeil@fredhutch.org

20

21

22 **Abstract**

23

24 Molnupiravir is an antiviral medicine that induces lethal copying errors into SARS-CoV-2 RNA.
25 Molnupiravir reduced hospitalization in one pivotal trial by 50% and had variable effects on
26 reducing viral RNA levels in three separate trials. We used mathematical models to simulate
27 these trials and closely recapitulated their virologic outcomes. Model simulations suggest lower
28 antiviral potency against pre-omicron SARS-CoV-2 variants than against omicron. We estimate
29 that in vitro assays underestimate in vivo potency 7-8 fold against omicron variants. Our model
30 suggests that because polymerase chain reaction detects molnupiravir mutated variants, the true
31 reduction in genetically intact viral RNA is underestimated by ~0.5 log in the two trials, which
32 included participants with omicron. Our results reinforce past work suggesting that in vitro
33 assays are unreliable for estimating in vivo antiviral drug potency and suggest that virologic
34 endpoints for respiratory virus clinical trials should be catered to the drug mechanism of action.

35

36

37

38

39

40

41

42 Introduction

43
44 Molnupiravir is an antiviral drug that induces errors in the SARS-CoV-2 genome, which
45 typically renders the virus unable to replicate further.¹ In the randomized double-blinded MOVE-
46 OUT trial, which enrolled unvaccinated individuals when delta, mu, and gamma variants of
47 concern (VOC) were circulating, molnupiravir reduced hospitalization by 50% and viral load
48 after treatment by 0.3 log relative to placebo.² In the platform adaptive PANORAMIC trial,
49 which enrolled vaccinated individuals when omicron VOCs were circulating, molnupiravir did
50 not lower hospitalization rates, which were only 1% in both arms, but lowered viral load after
51 treatment by 0.94 log relative to usual care.³ In the platform adaptive PLATCOV trial, which
52 enrolled low-risk individuals when omicron VOCs were circulating, molnupiravir lowered viral
53 load after treatment by 1.09 log relative to usual care.⁴ Taken together, these trials demonstrate
54 that molnupiravir has both clinical and virologic efficacy which varied across trials and viral
55 variants.

56
57 Overall, use of molnupiravir has been lower than that of nirmatrelvir / ritonavir based on lower
58 reduction in hospitalization in MOVE-OUT relative to the EPIC-HR trial for nirmatrelvir /
59 ritonavir.⁵ A concern has also been raised that molnupiravir's mechanism of action could
60 generate novel mutants that persist after cessation of treatment,⁶ and then spread in the
61 population.⁷ Nevertheless, PANORAMIC and PLATCOV results suggest high potency, and
62 molnupiravir is still considered in individuals in whom nirmatrelvir / ritonavir is contraindicated,
63 and in combination with other drugs in immunocompromised hosts.^{8,9} There is currently no
64 explanation for the disparate antiviral effects in MOVE-OUT versus PANORAMIC and
65 PLATCOV. Moreover, the fact that polymerase chain reaction (PCR) detects drug-altered viral
66 RNA molecules⁶ has not always been considered in the analysis of trial outcomes.

67
68 We previously used clinical trial simulation to reproduce results from nirmatrelvir / ritonavir
69 trials for SARS-CoV-2.^{10,11} We first validated a viral immune dynamic model (VID) against a
70 very large prospective cohort of infections that included multiple VOCs.¹¹ We used diverse
71 virologic output from this model to create simulated cohorts for the control arms of trials. We
72 then layered pharmacokinetic (PK) and pharmacodynamic (PD) models for nirmatrelvir /
73 ritonavir on the VID models to simulate treatment arms.¹⁰ This approach recapitulated mean viral
74 load reduction in the EPIC-HR and PLATCOV trials, as well as individual viral load trajectories
75 in PLATCOV. The validated model was then used to explain the high frequency of virologic and
76 concurrent symptomatic rebound with use in the community,¹² despite very low levels of
77 virologic and symptomatic rebound in the EPIC-HR trial.^{13,14} Model output suggests that
78 extending therapy from 5 to 10 days would nearly eliminate rebound,¹⁰ a result confirmed with
79 modeling of separate data by another group.¹⁵

80
81 Here we expand this approach to develop a new joint VID-PK-PD model to account for the
82 unique mechanism of action of molnupiravir. We simulate by fitting the model to results from the
83 MOVE-OUT, PLATCOV and PANORAMIC trials. Our results suggest that quantitative viral
84 PCR likely underestimates the reduction in non-mutated viral RNA and therefore the true
85 potency of molnupiravir during omicron infections.

86
87

88

89


90 Results

91

92 Viral immune dynamic, pharmacokinetic and pharmacodynamic clinical trial simulation 93 models.

94 We previously described our viral immune dynamic (VID) model that was fit to diverse viral
95 loads from 1510 SARS-CoV-2 infected individuals in the National Basketball Association
96 cohort.^{11, 16} The model assumes a finite number of susceptible cells. An eclipse phase delays viral
97 production by infected cells. In keeping with an early innate immune response, susceptible cells
98 become refractory to infection in the presence of infected cells but also revert to a susceptible
99 state at a constant rate. Infected cells are cleared by cytolysis and delayed acquired immunity,
100 which is activated in a time-dependent fashion (**Fig 1a**). We used a mixed-effect population
101 approach implemented in Monolix to estimate model parameters.¹⁷

102




103

104 **Fig 1. Schematic of the (a) viral dynamic model and (b) molnupiravir PK-PD model.**

105

106 To reproduce levels of molnupiravir, we used a three-compartment pharmacokinetic (PK) model
107 (**Fig. 1b**). Using Monolix and the mixed-effect population approach, we estimated parameter
108 values by fitting the model to the average plasma concentration of healthy subjects.¹⁸ The model
109 closely recapitulated observed drug levels following multiple doses of 50, 100, 200, 300, 400,
110 600, and 800 mg given twice daily for five days (**Fig S1, Table S1**). The estimated value for the
111 transition rate from plasma to peripheral compartment () was dose-dependent in the form of
112 . All other PK parameters were dose independent. For the pharmacodynamic
113 (PD) model, we assumed drug efficacy follows a Hill equation with respect to concentration. We
114 parameterized the model using in vitro efficacy data collected at different concentrations (details
115 in **Materials and Methods, Fig S2, Table S2**).¹⁹


116 We combined the VID and PKPD models by using treatment efficacy to convert non-mutated
117 virus to mutated virus, both of which are assumed to be detected with polymerase chain reaction
118 (PCR) assays, given the low probability of drug-induced mutations in the PCR primer region.
119 This assumption is based on the observed drug-induced mutation of approximately 1 in 2000
120 sites.²⁰ Given the average length of most PCR primers of ~25 base pairs, the chance of the
121 primer remaining unmutated after treatment is $(1999/2000)^{25}$, or 98.76%. A limitation of viral
122 load data from the included clinical trials is that it lacks early pre-symptomatic endpoints to
123 estimate the viral expansion slope. To further train the model, we included 1023 Omicron-
124 infected participants from the NBA cohort to inform rates of viral upslope in the trials.¹¹ We first
125 fit the combined model to individual viral load data from 149 low-risk, symptomatic vaccinated
126 participants infected with omicron VOCs in the PLATCOV trial (65 treated and 84 controls) and
127 from 80 high-risk, symptomatic vaccinated participants infected with omicron VOCs in the
128 PANORAMIC trial (38 treated and 42 controls) (Fig 2a, 2b, Fig S3, S4, S5, S6). We next fit the
129 combined model to trial endpoint data (mean viral load drop from baseline) reported in three
130 randomized, controlled trials: PLATCOV (Fig 3a, 4a-d),⁴ PANORAMIC (Fig 3b, 4e-h),³ and
131 the MOVE-OUT trial with 1093 high-risk unvaccinated symptomatic individuals infected with
132 pre-omicron VOCs (549 treated + 544 placebo, Fig 3c, 4i-k).² All model fitting was using
133 Monolix with non-linear mixed effects approaches described in the **Materials and Methods**.



135 **Fig 2. Mathematical model fits of SARS-CoV-2 viral load over time to a subset of study participants**
136 **in PLATCOV and PANORAMIC receiving no treatment (control) or molnupiravir. (a) Model fits**
137 **to 9 control and 9 treatment participants in PLATCOV. (b) Model fits to 9 control and 9 treatment**
138 **participants in PANORAMIC. (c) Individual estimates for potency adjustment factor (ratio of *in vivo* :**
139 ***in vitro* EC50) in the two trials.**

140 **Model fitting to individual viral load trajectories in PLATCOV and PANORAMIC.**

141 For each participant, we defined the in vivo EC_{50} as the plasma drug concentration required to
142 inhibit viral replication by 50% and the potency adjustment factor (paf) as the ratio between the
143 in vivo and in vitro EC_{50} .^{21, 22} To estimate the paf, we fit the combined VID-PKPD model to
144 individual viral load data of both arms of PLATCOV and PANORAMIC trials and Omicron
145 infected individuals in the NBA cohort using the population mixed effect approach in Monolix.
146 We achieved good model fit to individual viral load trajectories in the control and treatment arms
147 of PLATCOV (Fig 2a, Fig S3, S4) and PANORAMIC (Fig 2b, S5, S6). The model projected
148 higher levels of total detected SARS-CoV-2 RNA in most participants relative to non-mutated
149 viral RNA (Fig 2a,b). We estimated a range of individual paf values with similar mean and
150 median values estimated for both trials (Fig 2c). These values suggest that in vivo potency of
151 molunpiravair is on average 7-8 fold higher than in in vitro estimates. Each participant had an
152 estimated paf less than one indicating that enhanced potency is necessary to include to optimize
153 fit to the data.
154




155
156 **Figure 3. Mean viral load reduction in (a) PLATCOV, (b) PANORAMIC, and (c) MOVE-OUT**
157 **which are targets for model fitting.**

158
159 **Model fit to trial virologic endpoint data from PLATCOV, PANORAMIC, and MOVE-**
160 **OUT.**

161 As a second approach, we assessed whether a virtual cohort strategy where control participants
162 are modeled from pre-existing cohorts can predict virologic trial endpoints. This approach is
163 necessary for situations where individual viral load data are not available as with MOVE-OUT
164 and is important as it demonstrates that the model can reproduce the primary virologic endpoint
165 of the study. We simulated virtual cohorts using the combined VID-PKPD model and fit results
166 to viral load decay from baseline in the three trials. For each trial arm, we randomly selected 400
167 individuals from the NBA cohort with the closest matching viral variant, symptom, and vaccine
168 status and used their estimated individual viral dynamic parameters in simulations. To address

169 variability in timing of baseline viral load measurement relative to infection, we randomly
 170 assigned all individuals an incubation period selected from a variant-specific gamma distribution
 171 found in the literature.^{23, 24} Treatment start day was randomly selected from a distribution based
 172 on observed enrollment windows in the three trials. Due to the lack of individual PK data, the
 173 same estimated population PK parameters were used for all simulated treated individuals
 174 (Table S1). PD parameters were randomly selected from a log-normal distribution with
 175 estimated mean and standard error (Table S2).

176 Our model closely reproduced kinetics of viral decay in PLATCOV in control (Fig 3a, 4a) and
 177 treatment arms (Fig 3a, 4b) and estimated a $paf=0.13$ (Fig 4c) similar to our mean estimate using
 178 individual fits (Fig 2c). The model also predicted individual-level variability in virologic
 179 responses observed in PLATCOV, including instances of increased viral load following therapy
 180 (Fig 4d). We compared simulated and actual distributions of viral load change among trial
 181 participants in the control and treatment arms. On most post-treatment days, simulated and actual
 182 distributions were not statistically dissimilar. Wider distributions of observed versus simulated
 183 viral load change were noted on post-randomization days 1 and 2 for control and treatment (Fig
 184 4d), likely due to noise in viral load data from oral swabs: differences of 1–2 logs were often
 185 noted between replicates collected from PLATCOV participants at equivalent timepoints,
 186 particularly on days 1 and 2.¹⁰
 187



188
 189 **Figure 4. Model fit to virologic trial outcomes for (a-d) PLATCOV, (e-h) PANORAMIC, (i-k)**
 190 **MOVE-OUT. Results include (a, e, i) control groups, (b, f, j) treatment groups, (d,h) comparing**
 191 **individual variability of data vs simulation in control and treatment arms, and (c, g, k) estimate for**
 192 **potency adjustment factor. To only capture the effect of treatment and address potential identifiability**
 193 **issues, data from the first seven days after baseline were used to estimate the paf. Therefore, the crossed-**
 194 **out data points were not included in the calculation of the R².**
 195


196 Similarly, our model closely reproduced kinetics of viral decay in PANORAMIC in control (Fig
 197 3b, 4e) and treatment arms (Fig 3b, 4f) and estimated a $paf=0.19$ (Fig 4g) similar to our mean
 198 estimate using individual fits (Fig 2c). The model also predicted individual-level variability in

199 virologic responses observed in PANORAMIC, including instances of increased viral load
 200 following therapy (Fig 4h). We compared simulated and actual distributions of viral load change
 201 among trial participants in the control and treatment arms. On all post-treatment days other than
 202 day 2 control, simulated and actual distributions were not statistically dissimilar (Fig 4h). This
 203 likely indicates less noise in viral load data from nasopharyngeal swabs collected in
 204 PANORAMIC relative to oral swabs in PLATCOV.

205
 206 Finally, the model reproduced kinetics of viral decay in MOVE-OUT in control (Fig 4i) and
 207 treatment arms (Fig 4j) but estimated a higher $paf=2.64$ (Fig 4k). The higher paf maps to the far
 208 less substantial viral load reduction in MOVE-OUT relative to the other two trials which in turn
 209 may be explained by less potency against pre-omicron variants which has been observed
 210 experimentally.²⁵

211
 212 As a further validation step, we performed counterfactual simulations which assess viral kinetics
 213 of control study participants assuming treatment and treatment participants assuming
 214 placebo/usual care. Counterfactual control simulations slightly overestimated late viral loads for
 215 PLATCOV (Fig S7a) and PANORAMIC (Fig S8a). This may be because therapy suppresses
 216 acquired immune responses, which is not captured in our model.¹⁵ Counterfactual treatment
 217 simulations fit the data well for PLATCOV (Fig S7b) and PANORAMIC (Fig S8b). Simulations
 218 occasionally predicted viral rebound following treatment (Fig S7c,d and S8c,d).

219
 220




221
 222 **Figure 5. PCR underestimates the true reduction in non-mutated SARS-CoV-2 RNA in PLATCOV**
 223 **and PANORAMIC but not MOVE-OUT.** Simulated mean viral loads including non-mutated viral RNA
 224 in (a) PLATCOV, (b) PANORAMIC and (c) MOVE-OUT. (d) Individual reduction at day 5 in the
 225 simulated control group (blue), simulated total viral RNA (grey) and simulated non-mutated viral RNA
 226 (pink) in the three trials showing no statistical difference between total and non-mutated viral RNA

227 despite a lower median. (e) Individual viral area under the curve from the start of the treatment through
 228 day 5 in the simulated control group (blue), simulated total viral RNA (grey), and simulated non-mutated
 229 viral RNA (pink) in the three trials showing a statistical difference between total and non-mutated viral
 230 RNA. Boxplots include the interquartile range (IQR) with whiskers equaling 1.5 the IQR. (f) Table of
 231 mean viral load reductions in the trials and simulations including the predicted mean difference in total
 232 versus mutated viral RNA.

233
 234 **Estimates of reduction in fully mutated viruses versus non-mutated SARS-CoV-2 RNA.**
 235 We used our optimized model with solved paf to project the trajectory of non-mutated viral RNA
 236 during treatment relative to values measured with PCR, which detects viral RNA with drug-
 237 induced mutations.⁶ In PLATCOV (Fig 5a,d,f) and PANORAMIC (Fig 5b,d,f), owing to higher
 238 drug potency, total SARS-CoV-2 viral RNA on treatment exceeded non-mutated viral RNA by
 239 ~0.48 and 0.59 log respectively, suggesting that measured endpoints underestimate the drug's
 240 true antiviral effect. However, these differences did not achieve statistical significance, perhaps
 241 because estimated total and non-mutated viral RNA levels converge at drug trough. In MOVE-
 242 OUT (Fig 5c,d,f), there was no significant difference between total SARS-CoV-2 viral RNA on
 243 treatment and non-mutated viral RNA.

244



245
 246 **Figure 6. Relationship of drug pharmacokinetics and pharmacodynamics to in vivo potency and**
 247 **viral load reduction.** (a) Molnupiravir plasma concentration during five days of treatment with 800 mg
 248 molnupiravir given twice daily. The dashed lines mark the EC₅₀ with different paf values which differ by
 249 trial. For Paf = 0.13, drug levels are almost entirely above EC₅₀. (b) Dynamic shifts in molnupiravir
 250 efficacy for different paf values which differ by trial. Efficacy only drops minimally at trough levels when
 251 paf is low (i.e. 0.14 and 0.13 in PLATCOV and PANORAMIC) but drops significantly at trough levels in
 252 MOVE-OUT. (c) Drug potency of SARS-CoV-2 antivirals according to trial. The in-vivo efficacy of
 253 molnupiravir in PLATCOV and PANORAMIC trials is close to the in vivo efficacy of
 254 nirmatrelvir/ritonavir in the PLATCOV trial and higher than EPIC-HR. MOVE-OUT potency is
 255 significantly lower due to a higher paf and higher in vivo EC₅₀ value. (d) Simulated mean drops in total
 256 viral RNA from baseline relative to counterfactual placebo/usual care arms on day 5 in the three
 257 molnupiravir trials and two nirmatrelvir/ritonavir trials. (e) Simulated mean drops in non-mutated viral
 258 RNA from baseline relative to counterfactual placebo on day 5 in the three molnupiravir trials and two
 259 nirmatrelvir/ritonavir trials. In the molnupiravir trials, total viral RNA drops less than non-mutated viral

260 RNA due to PCR detection of drug-mutated viral RNA. Total possible reduction in non-mutated SARS-
261 CoV-2 RNA is less for MOVE-OUT than PLATCOV and PANORAMIC due to higher initial viral loads
262 and lower values of detection in the trials.

263
264 In all 3 trials, the models suggest that non-mutated viral loads during treatment may be lowest at
265 drug peak, reflecting the short plasma half-life of molnupiravir. Therefore, the cumulative
266 effective of drug is best estimated with viral area under the curve which accounts for highly
267 variable drug activity over time due to short drug half-life. By this estimate, the reduction in non-
268 mutated viral RNA far exceeds that of total measured viral RNA (**Fig 5e**). In the case of MOVE-
269 OUT, this may explain why significant clinical benefit is associated with only a marginal
270 reduction in observed decline in total viral RNA. This also suggests that there might be utility to
271 measure viral load after drug peak and trough for agents with short half-life as viral loads may
272 differ by a full order of magnitude according to drug level.

273
274 **Differences in trial participants and model parameters.**

275 We also compared features of each trial as they related to model predictions by assessing the
276 viral dynamic range in each trial (**Fig S9a**). Control participants in PLATCOV had lower mean
277 viral loads throughout the course of infection relative to PANORAMIC and MOVE-OUT (**Fig**
278 **S9b**). Given PLATCOV and PANORAMIC enrolled participants with the omicron variant, we
279 surmise that these differences relate to demographic differences in study participant
280 demographics, slightly shorter estimated time to treatment in PANORAMIC versus PLATCOV
281 estimated by our model (t_0 in **Fig S10**), and/or characteristics of the PCR assay used in the
282 studies. The trials also employed different limits of detection which impacted observed
283 reductions in viral load (**Fig S9b**). Model parameters were largely equivalent between studies
284 and between treatment and control arms, reflecting the flexibility of the model (**Fig S10**). The
285 parameter governing transition of susceptible cells to a refractory state was higher in PLATCOV
286 relative to PANORAMIC which likely was necessary to achieve lower viral loads overall and
287 may reflect the younger study participants (**Fig S10**).

288
289 **Antiviral potency, viral load assessment and trial design all impact observed antiviral**
290 **reduction.**

291 We next combined PK and PD models to assess the average efficacy of the drug during days 0-5
292 in all three trials (**Fig 6a,b**) and noted an efficacy of 53% in MOVE-OUT (**Fig 6c**). The efficacy
293 of molnupiravir in PLATCOV (94%) and PANORAMIC (95%) was similar to that of
294 nirmatrelvir in PLATCOV (94%) and EPIC-HR (82%) owing to a much lower paf for
295 molnupiravir relative to nirmatrelvir / ritonavir (**Fig 6c**).

296
297 These potencies mapped to different reductions in viral load relative to placebo/usual care. Total
298 viral RNA reduction in PANORMIC and PLATCOV exceeded that in MOVE-OUT owing to
299 lower paf (**Fig 6d**), but also due to a larger viral dynamic range (defined as the distance from
300 baseline viral load to the lower threshold PCR (LOD) (**Fig S9b**)), which allows for a greater
301 observed reduction in viral load. PANORAMIC used LOD = 100 (imputed as 50), and
302 PLATCOV had $\text{LOD} \cong 18$ (copies/ml), versus LOD = 500 copies/ml for MOVE-OUT.
303 PANORAMIC also had much higher average starting viral loads (7.4 log₁₀ (copies/ml)) versus
304 PLATCOV (5.8 log₁₀ copies/ml) and MOVE-OUT (6.8 log₁₀ copies/ml) (**Fig S9b**).
305 Molnupiravir approached maximal possible total viral load viral RNA reduction in

306 PANORAMIC and PLATCOV, whereas protease inhibitors could still achieve greater viral load
307 reduction at lower paf (**Fig 6d**) as recently observed with ensitrelvir.²⁶

308
309 The greater possible reduction in total viral load for protease inhibitors relative to molnupiravir
310 owes to different mechanisms of action. Model projected reductions in non-mutated viral RNA
311 reduction in PANORMIC and PLATCOV approximated viral load reductions observed in EPIC-
312 HR and PLATCOV on nirmatrelvir / ritonavir (**Fig 6e**), suggesting that PCR detection of mutated
313 viruses underestimates true molnupiravir potency and that a more potent mutagenic agent could
314 accrue further virologic benefit.

315
316 **Optimization of molnupiravir therapy to avoid viral rebound.**

317 Instances of viral rebound were observed in PLATCOV and PANORAMIC and have been
318 observed following molnupiravir treatment.^{4, 27} We analyzed higher doses and prolonged therapy
319 and noted that as with nirmatrelvir, prolonging therapy is a better method to prevent rebound
320 than increasing dose (**Fig S11**).

321

322

323

324 Discussion

325
326 We recapitulated the virologic results of three clinical trials of molnupiravir with our combined
327 clinical trial simulation VID/PK/PD models. Model output highlights key differences in viral
328 load reduction between the trials and identifies mechanistic differences to explain this. The
329 MOVE-OUT trial was associated with significantly less reduction in viral load between treatment
330 and control arms than the other two trials. Accordingly, the drug efficacy (0.53) was lower in this
331 trial, and our estimate for paf was 2.64, signifying marginally lower potency in vivo than in vitro.
332 This result is compatible with 0.4-fold lower median EC50 values for molnupiravir in vitro
333 against omicron relative to prior variants.²⁵ The higher paf in MOVE-OUT permitted drug
334 troughs below the EC50, limiting potency throughout the dosing interval. In PLATCOV and
335 PANORAMIC, our model suggests drug levels remain above the in vivo EC50 throughout the
336 dosing interval though potency does fluctuate according to drug level.

337
338 The estimated drug efficacy in PLATCOV and PANORAMIC was considerably higher (0.94 and
339 0.95, respectively), and the paf was estimated to be 0.14 and 0.13, indicating greater potency in
340 vivo than in vitro. We have applied our clinical trial simulation technique to multiple drugs for
341 SARS-CoV-2,¹⁰ HSV-2,^{21, 22} and HIV,²⁸ and this is the first time we have identified this trend.
342 Allowing molnupiravir to be more potent in vivo in our modeling of PLATCOV and
343 PANORAMIC was necessary to capture the much greater reduction in total viral RNA relative to
344 off-treatment in these studies (1.09 log and 0.94 log respectively versus 0.3 log in MOVE-OUT).

345
346 A key outcome of our analysis is that SARS-CoV-2 PCR likely underestimates molnupiravir
347 potency because it still detects drug-mutated viral RNA.⁶ This appears to be most significant
348 when antiviral potency is higher, as in PANORAMIC and PLATCOV, leading to a 0.48-0.59 log
349 underestimation of reduction in non-mutated virus. Our results suggest that use of standard PCR
350 for assessing SARS-CoV-2 levels may lead to underestimation of drug potency. Multi probe
351 assays as have been used for the HIV reservoir may improve specificity for viruses that remain
352 intact and replication competent.²⁹ Viral culture is potentially a useful metric but lacks sufficient
353 sensitivity and precision and is too labor intensive to serve as a viable trial endpoint.¹²

354
355 Our results suggest that viral loads may vary according to drug level given molnupiravir's short
356 plasma half-life. A sub-study within future trials comparing viral loads between drug trough and
357 peak would be useful for the field. This could validate our model's prediction that even small
358 reductions in viral RNA may be associated with substantial reductions in total viral area under
359 the curve (a surrogate for infection surface area) particularly with a short half-life drug. Even
360 minor reductions in viral load may be associated with substantial clinical benefit in this case.
361 These fluctuations may be less evident if the intra-cellular half-life of the drug is longer or if PK
362 measures in our model underestimate true drug levels in PANORMIC due to older age or
363 impaired renal clearance. Model accuracy would be improved if viral load and PK data were
364 available from the same patients in similar trials.

365
366 Another key practical outcome is that as for nirmatrelvir, extension of molnupiravir therapy to 10
367 days is likely to prevent rebound though our simulations do not suggest any benefit from
368 increasing dose.¹⁰ This suggests that prolonging therapy or using longer half-life agents is ideal
369 for treating SARS-CoV-2.³⁰

370

371 Each trial represented a unique set of issues for model fitting. In MOVE-OUT, because the
372 treatment arm mean viral kinetics curve differed only slightly from the control arm, the model
373 without drug provided reasonable fit to the treatment arm. Nevertheless, the paf was identifiable
374 for this trial indicating that the model was able to detect and specify the very limited potency of
375 the drug. The fact that the drug's potency and clinical efficacy appears to have increased with
376 introduction of the omicron variant demonstrates a massive challenge for the therapeutics field:
377 as with vaccines, trials performed when prior variants were circulating may prove less relevant
378 as new variants continually emerge. A priority should be retesting existing agents against newly
379 emerging variants in small nimble trials such as PLATCOV, with viral load endpoints.

380

381 For PLATCOV, the model for the treatment arm matched the trial data very precisely and
382 identified the paf. The drug achieved nearly maximal observed viral load reduction in this trial.
383 We identified a similar trend for PANORAMIC. It is notable that the model had the flexibility to
384 account for different viral loads between these trials by predicting more rapid innate immune
385 responses in PLATCOV.

386

387 We arrived at similar estimate for paf in PLATCOV and PANORAMIC, while using two separate
388 methods: fitting to individual viral loads and fitting to mean viral load reduction trial endpoints.
389 This suggests that our approach using in silico cohorts and fitting to population level outcomes
390 produces reliable results.¹⁰ In many cases, it remains challenging for academics to obtain
391 individualized data from industry sponsored trials. Therefore, it is important that the endpoint
392 fitting approach should be considered when this is the only data available.

393

394 Finally, our results highlight challenges in trial design associated with the selection of PCR
395 assays and limits of detection. Different limits of detection were selected for each trial which in
396 turn impacts the degree of viral load decrease that can be observed. Initial viral loads were
397 notably higher in PANORAMIC and MOVE-OUT than PLATCOV. The equivalent viral loads
398 between PANORAMIC and PLATCOV may reflect a more sensitive PCR in the PANORAMIC
399 study as past immunity has consistently predicted lower viral loads and more rapid viral
400 elimination for omicron variants.^{11, 31} On the other hand, PANORMIC viral loads could have
401 been higher than in PLATCOV despite both enrolling omicron infections due to an older and less
402 healthy population. Ideally, equivalent internationally standardized PCR quantitation would be
403 used across all trials.

404

405 Our study has a couple of limitations. The estimated paf is based on the in vitro assay data
406 against delta variant in Calu-3 cells. In vitro EC50 is sensitive to assay conditions, including cell
407 type, the variant of concern, the multiplicity of infection (MOI), and specific lab. In general, the
408 inability of in vitro assays to match in vivo conditions makes it an unreliable proxy for the in
409 vivo potency of the drug and explains the necessity of incorporating the paf parameter when
410 simulating an antiviral clinical trial.

411

412 In our model, we assumed all mutated viruses are noninfectious. While most drug-induced
413 random mutations reduce the fitness/viability of the virus, the molnupiravir mutation signature
414 has been detected in circulating variants, especially in regions where the drug has been used most
415 commonly.⁷ Furthermore, in the PANORAMIC study, no statistical difference was observed

416 between the rate of culturable samples in the treatment and control arms which implies some
417 mutated viruses might be transmissible.³²

418
419 PK parameters were estimated using the data from the plasma concentration of healthy
420 individuals with the age range of 19-60 (mean 39.6) years old. The clearance rate of renally
421 cleared drugs often increase with age.³³ This implies that the paf may be larger in an older
422 population, such as in PANORAMIC participants. Further, we used the plasma concentration in
423 the PD model to calculate the drug efficacy. However, using the drug's intracellular
424 concentration with a longer half-life, represented by the central compartment of the PK model,
425 would also likely lead to a larger estimated paf.

426
427 In summary, we further demonstrate the utility of clinical trial simulation using models that
428 capture drug PK and PD, as well as infection dynamics. In the case of molnupiravir, our results
429 suggest that final viral endpoints should be adjusted based on the drug's mechanism of action.

430
431

432 **Materials and Methods**

433

434 **Study Design.**

435 We developed a viral dynamics model recapitulating viral load data collected from symptomatic
436 individuals in the NBA (National Basketball Association) cohort.¹¹ We used a two-compartment
437 model to reproduce the PK data of molnupiravir.¹⁸ For clinical trial simulation, we constructed a
438 virtual cohort by randomly selecting 400 individuals from the NBA cohort, trying to match the
439 trial populations regarding vaccine status and history of infection. Due to lack of individual PK
440 data, we used estimated population PK parameters for all individuals in the virtual cohort. The
441 PD parameters for each individual were randomly selected from a log-normal distribution with
442 their estimated means and standard errors. We fit the combined viral dynamic and PKPD model
443 to the average change in viral load from the baseline of the control and treatment arms of three
444 previously published molnupiravir clinical trials.^{2-4, 34} Comparing our model to the control arms
445 validated our viral dynamic model and demonstrated how well our virtual cohorts represent the
446 trial control arms. We used the average data from the treatment arms to estimate the potency
447 adjustment factor (paf) by maximizing the R^2 of the fit.¹⁰ We also fit to individual viral load
448 trajectories in PLATCOV and PANORAMIC using the mixed-effect population approach
449 implemented in Monolix³⁵⁻³⁷ and obtained both individual paf values and a population
450 distribution.

451 **Viral load data**

452 The NBA cohort dataset published by Hay et al consists of 2875 documented SARS-CoV-2
453 infections in 2678 people detected through frequent PCR testing regardless of symptoms.¹⁶ We
454 used the viral load data from 1510 infections in 1440 individuals that had at least 4 positive
455 quantitative samples to estimate viral dynamic parameters. We used parameter sets estimated for
456 the symptomatic subpopulation of these individuals to construct virtual cohorts.¹¹

457 **Clinical trial data**

458 We used viral load data from three molnupiravir clinical trials. MOVE-OUT by Jayk Bernal et al.
459 included 544 and 549 symptomatic high-risk individuals in the control and treatment arms,
460 respectively.² We obtained the average change in viral load data of the control and treatment
461 arms as shared in the supplementary material of their published manuscript in Table S6. Nasal
462 viral load was measured using PCR assay on days 0, 3, 5, 10, and 14 after the treatment start day
463 and adjusted by the baseline viral load. The lower limit of detection (LOD) of 500 copies/ml
464 were used in this trial. The treatment was started within five days of symptom onset.

465 PLATCOV by Schilling et al. is an open-label, randomized, controlled adaptive trial with 85 and
466 58 symptomatic, young, healthy individuals in the control and molnupiravir treatment arms,
467 respectively.⁴ The oropharyngeal samples from each participant were collected daily on days 0
468 through 7 and on day 14 after the treatment start day, and viral load was measured using PCR
469 assay. We used the individual viral load data published by the authors. From PLATCOV, we
470 averaged over the two oral samples collected from each individual and calculated viral load drop
471 from baseline or used the individual-level viral load data. We used the maximum LOD reported
472 in the published data (~1.26 log).

473 PANORAMIC is a platform adaptive randomized, controlled trial with 42 and 38 symptomatic,
474 vaccinated individuals with at least one risk factor in the control and treatment arms,

475 respectively.³ Nasal viral load was measured using PCR and samples were collected on days 0
476 through 6 and on day 13. We used individual viral load data shared by the authors and adjusted
477 by baseline viral load to obtain mean viral load drop from the baseline. Mean days since
478 symptom onset at baseline (sd) were 2.4 (0.78) for the treatment arm and 2.5(1.12) for the
479 control arm. The lower limit of detection of 100 copies/ml (imputed as 50 copies/ml) was used.

480 In all three trials, the study participants were treated with 800mg molnupiravir twice per day, for
481 five days.

482 **PK data**

483 Mean plasma concentration data of molnupiravir were obtained by digitizing Figure 3 of the
484 phase I trial by Painter et al. using WebPlotDigitizer.¹⁸ The data used in this paper belong to the
485 multiple-ascending part of the phase I trial where six participants were given 50, 100, 200, 300,
486 400, 600, and 800 mg of molnupiravir twice daily for 5.5 days, and their plasma concentrations
487 were measured after the first and last doses.

488 **PD data**

489 The data on drug efficacy was obtained from experiments performed at the University of
490 Washington. The efficacy of molnupiravir was measured against the delta variant of SARS-
491 CoV2 in Calu-3 cells (human lung epithelial). Briefly, Calu 3 cells were treated with varying
492 concentrations of molnupiravir prior to infection with SARS-CoV-2 (delta isolate) at a
493 multiplicity of infection of 0.01. Antiviral efficacy and cell viability (of non-infected cells treated
494 with drugs) were assessed as described.^{9, 10} There were five replicates per condition, pooled from
495 2 independent technical experimental repeats (one experiment with triplicate conditions, one
496 experiment in duplicate conditions).

497 **Viral dynamics model**

498 We used our model of SARS-CoV-2 dynamics to model the viral load of symptomatic
499 individuals with SARS-CoV-2 infection.¹¹ Our model assumes that susceptible cells (S) are
500 infected at rate βSV by SARS-CoV-2 virions. The infected cells go through a non-productive
501 eclipse phase (I_E) before producing viruses and transition to becoming productively infected
502 (I_P) at rate κI_E . When encountering productively infected cells, the susceptible cells become
503 refractory to infection (R) at the rate $\phi I_P S$. Refractory cells revert to a susceptible state at rate
504 ρR . The productively infected cells produce virus at the rate πI_P and are cleared at rate δI
505 representing cytolysis and the innate immune response that lacks memory and is proportional to
506 the amount of ongoing infection. If the infection persists longer than time τ , then cytotoxic
507 acquired immunity is activated, which is represented in our model by the rate $m I_P$. Finally, free
508 virions are cleared at the rate γ . Of note, this model, previously proposed by Ke et al. was
509 selected against other models based on superior fit to data and parsimony.³⁸ The model written as
510 a set of differential equations has the form,

511

$$512 \quad \frac{dS}{dt} = -\beta SV - \phi I_P S + \rho R \quad (1a)$$

$$513 \quad \frac{dR}{dt} = \phi I_P S - \rho R \quad (1b)$$

$$514 \quad \frac{dI_E}{dt} = \beta SV - \kappa I_E \quad (1c)$$

$$515 \quad \frac{dI_P}{dt} = \kappa I_E - \delta I_P - m(t)I_P \quad (1d)$$

$$516 \quad \frac{dV}{dt} = \pi I_P - \gamma V \quad (1e)$$

$$517 \quad \text{where } \begin{cases} m(t) = 0 & t < \tau \\ m(t) = m & t \geq \tau \end{cases} \quad (1f)$$

518

519 To estimate parameter values, we fit the model to viral load data from the NBA cohort using a
520 mixed-effect population approach implemented in Monolix. Details on the model selection and
521 fitting process can be found in Owens et al.¹¹

522 We start the simulations with 10^7 susceptible cells. The initial value of the refractory cells is
523 assumed to be zero since the interferon signaling is not active prior to infection. We further
524 assume there are no infected cells (eclipse or productive) at the beginning of the infection. We
525 fix the level of inoculum (V_0) at 97 copies/ml for each individual.

526 To resolve identifiability issues, we fixed two parameter values, setting the inverse of the eclipse
527 phase duration to $\kappa = 4$, and the rate of clearance of virions to $\gamma = 15$.¹¹

528 **PK model**

529 We used a two-compartmental PK model which includes the amount of drug in the GI tract
530 (A_{GI}), the plasma compartment (A_P), and the respiratory tract (A_L). The drug is administered
531 orally, passes through the GI tract and gets absorbed into the blood at the rate κ_a . The drug then
532 transfers from the blood into the peripheral compartment (or the lung) at the rate κ_{PL} . The
533 metabolized drug transfers back into the plasma at the rate κ_{LP} from where it clears from the
534 body at the rate κ_{CL} . The model in the form of ordinary differential equations is written as,

$$535 \quad \frac{dA_{GI}}{dt} = -\kappa_a A_{GI} \quad (2a)$$

$$536 \quad \frac{dA_P}{dt} = \kappa_a A_{GI} + \kappa_{LP} A_L - (\kappa_{CL} + \kappa_{PL}) A_P \quad (2b)$$

$$537 \quad \frac{dA_L}{dt} = \kappa_{PL} A_P - \kappa_{LP} A_L \quad (2c)$$

538

539 We used Monolix and a mixed-effect population approach to estimate the parameters and their
540 standard deviations. With the initial condition of ($A_{GI} = \text{Dose}$, $A_P = 0$, $A_L = 0$); we fit $C_P = \frac{A_P}{V_{ol}}$
541 to the plasma concentration data where V_{ol} is the estimated plasma volume. Details on
542 parameter values and the error model provided in **Table S1**.

543

544 **PD model**

545 For the pharmacodynamics model we used Hill equation, $\epsilon(t) = \frac{E_{max}C(t)^n}{C(t)^n + EC_{50}^n}$, where $C(t)$ is the
546 drug concentration in plasma, E_{max} is the maximum efficacy, n is the Hill coefficient, and EC_{50}
547 is the drug concentration in plasma required for 50% efficacy. We used least-squared fitting to

548 obtain the three parameters (E_{max} , n , and EC_{50}) and their standard deviations. The average drug
549 efficacy is measured using,

$$550 \quad E_{ave} = \frac{1}{t_{start} - t_{end}} \int_{t_{start}}^{t_{end}} \epsilon(t) dt \quad (3)$$

551 Where t_{start} and t_{end} are the treatment start day and end day, respectively.

552

553 **Combined PKPD and VL models**

554 The plasma concentration of molnupiravir obtained from the PK model is used in the PD model
555 to obtain time-dependent efficacy. Since molnupiravir imposes lethal mutations during the virus
556 replication process, in our model, a portion of produced viruses, measured by $\epsilon(t)$, are mutated
557 (V_m) and therefore assumed to be non-infectious, with the addition that most detected viral RNA
558 pre-treatment is also non-infectious. The production rate of non-mutated viruses is decreased by
559 a factor of $(1 - \epsilon(t))$. Equation 1e is written as,

$$560 \quad \frac{dV}{dt} = (1 - \epsilon(t))\pi I_P - \gamma V \quad (4a)$$

$$561 \quad \frac{dV_m}{dt} = (\epsilon(t))\pi I_P - \gamma V_m \quad (4b)$$

562 Total viral load ($V + V_m$) is used to fit the trial data.

563 **Fitting the combined model to individual viral load data in the PLATCOV trial**

564 We used the population mixed-effect approach and Monolix to estimate each individual's viral
565 dynamics parameters and the potency adjustment factor (paf). Due to the lack of data from the
566 initial phase of infection in the PLATCOV and PANORAMIC trials, we include the data from
567 Omicron-infected individuals in the NBA cohort to inform the model about the initial phase of
568 infection. We fixed the PK parameters to the estimated population values (**Table S1**), and the PD
569 parameters other than EC_{50} to the in vitro estimated population values (**Table S2**). We used the
570 study category (NBA vs PLATCOV and PANORAMIC) as a covariate for t_0 (timing of
571 infection) and τ (timing of the adaptive immune response) since the first recorded positive test is
572 likely much later for the clinical trials. In the NBA study, samples were collected almost daily
573 regardless of symptoms often leading to pre-symptomatic detection, while in the PLATCOV
574 study, the baseline measurement occurred after symptom onset, trial enrollment and consent.

575 **Construction of a virtual cohort**

576 To generate a cohort for our simulated clinical trials, we randomly selected 400 individuals (for
577 each arm of the simulated trials) from the unvaccinated symptomatic subpopulation of the NBA
578 cohort for MOVE-OUT and the vaccinated, Omicron infected subpopulation for PLATCOV and
579 PANORAMIC and used their individual viral load parameters estimated by fitting our viral
580 dynamics model to the data. A sample size of $n=400$ (out of 822 vaccinated individuals with
581 Omicron infection) was used to mimic a large-scale clinical trial and maintain relatively low
582 overlap between virtual cohorts used in each arm of the simulations and between different
583 simulations. Since the time of symptom onset is not available for all individuals in the NBA data,
584 we randomly drew an incubation period for each individual from gamma distributions with
585 variant-specific parameters estimated by Gamiche et al.³⁹ The start of treatment relative to
586 symptom onset was randomly selected according to a uniform distribution for MOVE-OUT and

587 PLATCOV, and a logit normal distribution for PANORAMIC with limits of [0,5] days and mean
588 and standard deviation reported in the PANORAMIC trial for control and treatment arms. The
589 same population PK parameters were assigned to each individual. The relevant dose in each
590 scenario was added to the A_{GI} compartment (the absorption equation) of the PK model (eq 2a) at
591 each dosing timepoint ($t=0, 0.5, 1, 1.5, \dots, 4.5$ days). For each dose, the appropriate PK
592 parameter were used (Table S1). PD parameters were also randomly drawn from a log-normal
593 distribution with the estimated mean and standard deviation. The standard deviation of the PD
594 parameters represents the accuracy of the assays and not individual variability.

595 **Potency adjustment factor (paf)**

596 The paf is defined as,

$$597 \quad \text{paf} = \frac{EC_{50, in vivo}}{EC_{50, in vitro}} \quad (5)$$

598

599 We estimated the paf by maximizing R^2 when fitting the change in viral load of the treatment
600 arm of our simulation to the data from day 0 to day 7 of the treatment arm of the clinical trial.

601

602 **Measuring rebound probability**

603 A viral load rebound in the treatment arm was defined when the viral load at any time after
604 treatment ended exceeded the viral load at the end of the treatment by 1 log. In the control group,
605 viral rebound was defined in patients who had at least two peaks with minimum height of 1000
606 copies/ml in their viral load trajectories and the second peak was 1 log higher than its preceding
607 local minimum.

608

609 **Software:**

610 All the model fittings in this study were performed using Monolix version 2023R1.

611 The data analysis and simulations were performed using Python 3.9.12.

612 **Data availability:**

613 The data analyzed in this work was previously published by Hay et al. and Schilling et al. and is
614 available on GitHub at

615 <https://github.com/gradlab/SC2-kinetics-immune-history> and
616 <https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0>

617 Pharmacodynamics data is available on GitHub at
618 <https://github.com/sEsmaeili/MolnupiravirModeling>

619

620 **Code availability:**

621 All codes and materials used in the analysis are available on GitHub

622 <https://github.com/sEsmaeili/MolnupiravirModeling>

623 **Funding:**

624 This work is supported by NIAID R01AI77512-01 (JTS, SP).

625 **References**

626

- 627 1. Abdelnabi R, Foo CS, De Jonghe S, Maes P, Weynand B, Neyts J. Molnupiravir Inhibits
628 Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. *J*
629 *Infect Dis.* 2021;224(5):749-53. doi: 10.1093/infdis/jiab361. PubMed PMID: 34244768;
630 PMID: PMC8408768.
- 631 2. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos
632 Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C,
633 Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, ..., Group M-OS.
634 Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med.*
635 2022;386(6):509-20. Epub 20211216. doi: 10.1056/NEJMoa2116044. PubMed PMID:
636 34914868; PMID: PMC8693688.
- 637 3. Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, Dorward
638 J, Lowe DM, Standing JF, Breuer J, Khoo S, Petrou S, Hood K, Nguyen-Van-Tam JS, Patel MG,
639 Saville BR, Marion J, Ogburn E, Allen J, ..., Group PTC. Molnupiravir plus usual care versus
640 usual care alone as early treatment for adults with COVID-19 at increased risk of adverse
641 outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. *Lancet.*
642 2023;401(10373):281-93. Epub 20221222. doi: 10.1016/S0140-6736(22)02597-1. PubMed
643 PMID: 36566761; PMID: PMC9779781.
- 644 4. Schilling WHK, Jittamala P, Watson JA, Boyd S, Luvira V, Siripoon T, Ngamprasertchai
645 T, Batty EM, Cruz C, Callery JJ, Singh S, Saroj M, Kruabkontho V, Ngernseng T,
646 Tanglakmankhong N, Tubprasert J, Abdad MY, Madmanee W, Kouhathong J, ..., Group PC.
647 Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early
648 symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive
649 trial. *Lancet Infect Dis.* 2024;24(1):36-45. Epub 20230928. doi: 10.1016/S1473-3099(23)00493-
650 0. PubMed PMID: 37778363; PMID: PMC7615401.
- 651 5. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M,
652 Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM, Investigators E-H. Oral
653 Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med.*
654 2022;386(15):1397-408. Epub 20220216. doi: 10.1056/NEJMoa2118542. PubMed PMID:
655 35172054; PMID: PMC8908851.
- 656 6. Fountain-Jones NM, Vanhaefen R, Williamson J, Maskell J, Chua IJ, Charleston M,
657 Cooley L. Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a
658 retrospective observational study. *Lancet Microbe.* 2024;5(5):e452-e8. Epub 20240322. doi:
659 10.1016/S2666-5247(23)00393-2. PubMed PMID: 38527471.
- 660 7. Sanderson T, Hisner R, Donovan-Banfield I, Hartman H, Løchen A, Peacock TP, Ruis C.
661 A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. *Nature.*
662 2023;623(7987):594-600. Epub 20230925. doi: 10.1038/s41586-023-06649-6. PubMed PMID:
663 37748513; PMID: PMC10651478.
- 664 8. Rosenke K, Lewis MC, Feldmann F, Bohrsen E, Schwarz B, Okumura A, Bohler WF,
665 Callison J, Shaia C, Bosio CM, Lovaglio J, Saturday G, Jarvis MA, Feldmann H. Combined
666 molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques.
667 *JCI Insight.* 2023;8(4). Epub 20230222. doi: 10.1172/jci.insight.166485. PubMed PMID:
668 36574296; PMID: PMC9977490.

- 669 9. Wagoner J, Herring S, Hsiang TY, Ianevski A, Biering SB, Xu S, Hoffmann M,
670 Pöhlmann S, Gale M, Aittokallio T, Schiffer JT, White JM, Polyak SJ. Combinations of Host-
671 and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. *Microbiol*
672 *Spectr.* 2022;10(5):e0333122. Epub 20221003. doi: 10.1128/spectrum.03331-22. PubMed PMID:
673 36190406; PMCID: PMC9718484.
- 674 10. Esmaili S, Owens K, Wagoner J, Polyak SJ, White JM, Schiffer JT. A unifying model to
675 explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic
676 efficacy. *Nat Commun.* 2024;15(1):5478. Epub 20240628. doi: 10.1038/s41467-024-49458-9.
677 PubMed PMID: 38942778; PMCID: PMC11213957.
- 678 11. Owens K, Esmaili S, Schiffer JT. Heterogeneous SARS-CoV-2 kinetics due to variable
679 timing and intensity of immune responses. *JCI Insight.* 2024;9(9). Epub 20240404. doi:
680 10.1172/jci.insight.176286. PubMed PMID: 38573774; PMCID: PMC11141931.
- 681 12. Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, Choudhary MC,
682 Gilbert RF, Reynolds Z, Li Y, Tien D, Sagar S, Vyas TD, Kawano Y, Sparks JA, Hammond SP,
683 Wallace Z, Vyas JM, Barczak AK, ..., Siedner MJ. SARS-CoV-2 Virologic Rebound With
684 Nirmatrelvir-Ritonavir Therapy : An Observational Study. *Ann Intern Med.* 2023;176(12):1577-
685 85. Epub 20231114. doi: 10.7326/M23-1756. PubMed PMID: 37956428; PMCID:
686 PMC10644265.
- 687 13. Harrington PR, Cong J, Troy SB, Rawson JMO, O'Rear JJ, Valappil TI, McGarry
688 Connelly S, Farley J, Birnkrant D. Evaluation of SARS-CoV-2 RNA Rebound After
689 Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials -
690 United States and International Sites, 2021-2022. *MMWR Morb Mortal Wkly Rep.*
691 2023;72(51):1365-70. Epub 20231222. doi: 10.15585/mmwr.mm7251a2. PubMed PMID:
692 38127674; PMCID: PMC10754264.
- 693 14. Anderson AS, Caubel P, Rusnak JM, Investigators E-HT. Nirmatrelvir-Ritonavir and
694 Viral Load Rebound in Covid-19. *N Engl J Med.* 2022;387(11):1047-9. Epub 20220907. doi:
695 10.1056/NEJMc2205944. PubMed PMID: 36069818; PMCID: PMC9513855.
- 696 15. Perelson AS, Ribeiro RM, Phan T. An explanation for SARS-CoV-2 rebound after
697 Paxlovid treatment. *medRxiv.* 2023:2023.05.30.23290747. doi: 10.1101/2023.05.30.23290747.
- 698 16. Hay JA, Kissler SM, Fauver JR, Mack C, Tai CG, Samant RM, Connolly S, Anderson DJ,
699 Khullar G, MacKay M, Patel M, Kelly S, Manhertz A, Eiter I, Salgado D, Baker T, Howard B,
700 Dudley JT, Mason CE, ..., Grad YH. Quantifying the impact of immune history and variant on
701 SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study. *Elife.* 2022;11.
702 Epub 20221116. doi: 10.7554/eLife.81849. PubMed PMID: 36383192; PMCID: PMC9711520.
- 703 17. Clairon Q, Pasin C, Balelli I, Thiébaud R, Prague M. Parameter estimation in nonlinear
704 mixed effect models based on ordinary differential equations: an optimal control approach.
705 *Computational Statistics.* 2023. doi: 10.1007/s00180-023-01420-x.
- 706 18. Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, Morin MJ,
707 Szewczyk LJ, Painter GR. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a
708 Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. *Antimicrob*
709 *Agents Chemother.* 2021;65(5). Epub 20210301. doi: 10.1128/AAC.02428-20. PubMed PMID:
710 33649113; PMCID: PMC8092915.
- 711 19. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, Zhou Y, Pitt E,
712 Anderson KS, Acosta EP, Siliciano RF. Dose-response curve slope sets class-specific limits on
713 inhibitory potential of anti-HIV drugs. *Nature Medicine.* 2008;14(7):762-6. doi:
714 10.1038/nm1777.

- 715 20. Zhou S, Long N, Rosenke K, Jarvis MA, Feldmann H, Swanstrom R. Combined
716 Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced
717 Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations. *J Infect*
718 *Dis.* 2024. Epub 20240708. doi: 10.1093/infdis/jiae213. PubMed PMID: 38973065.
- 719 21. Schiffer JT, Swan DA, Corey L, Wald A. Rapid viral expansion and short drug half-life
720 explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.
721 *Antimicrob Agents Chemother.* 2013;57(12):5820-9. Epub 2013/09/11. doi:
722 10.1128/AAC.01114-13. PubMed PMID: 24018260; PMCID: PMC3837890.
- 723 22. Schiffer JT, Swan DA, Magaret A, Corey L, Wald A, Ossig J, Ruebsamen-Schaeff H,
724 Stoelben S, Timmler B, Zimmermann H, Melhem MR, Van Wart SA, Rubino CM, Birkmann A.
725 Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial
726 outcomes. *Sci Transl Med.* 2016;8(324):324ra15. Epub 2016/02/05. doi:
727 10.1126/scitranslmed.aad6654. PubMed PMID: 26843190; PMCID: PMC4880060.
- 728 23. Backer JA, Eggink D, Andeweg SP, Veldhuijzen IK, van Maarseveen N, Vermaas K,
729 Vlaemynck B, Schepers R, van den Hof S, Reusken CB, Wallinga J. Shorter serial intervals in
730 SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands,
731 13 to 26 December 2021. *Euro Surveill.* 2022;27(6). doi: 10.2807/1560-
732 7917.ES.2022.27.6.2200042. PubMed PMID: 35144721; PMCID: PMC8832521.
- 733 24. Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation Period of COVID-19 Caused
734 by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis. *JAMA Netw Open.*
735 2022;5(8):e2228008. Epub 20220801. doi: 10.1001/jamanetworkopen.2022.28008. PubMed
736 PMID: 35994285; PMCID: PMC9396366.
- 737 25. Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, Bruno MJ,
738 Peppelenbosch MP, Haagmans BL, Pan Q. SARS-CoV-2 Omicron variant is highly sensitive to
739 molnupiravir, nirmatrelvir, and the combination. *Cell Res.* 2022;32(3):322-4. Epub 20220120.
740 doi: 10.1038/s41422-022-00618-w. PubMed PMID: 35058606; PMCID: PMC8771185.
- 741 26. Yotsuyanagi H, Ohmagari N, Doi Y, Yamato M, Bac NH, Cha BK, Imamura T, Sonoyama
742 T, Ichihashi G, Sanaki T, Tsuge Y, Uehara T, Mukae H. Efficacy and Safety of 5-Day Oral
743 Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized
744 Clinical Trial. *JAMA Netw Open.* 2024;7(2):e2354991. Epub 20240205. doi:
745 10.1001/jamanetworkopen.2023.54991. PubMed PMID: 38335000; PMCID: PMC10858401.
- 746 27. Cruciani M, Pati I, Masiello F, Piccinini V, Pupella S, De Angelis V. SARS-CoV-2
747 infection rebound among patients receiving antiviral agents, convalescent plasma, or no
748 treatment: a systematic review with meta-analysis. *Blood Transfus.* 2024. Epub 20240527. doi:
749 10.2450/BloodTransfus.764. PubMed PMID: 38814880.
- 750 28. Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska
751 M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen
752 P, Morris L, Mkhize NN, Williamson C, Mullins JI, ..., Edupuganti S. High monoclonal
753 neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated
754 Prevention trials. *Nat Commun.* 2023;14(1):8299. Epub 20231214. doi: 10.1038/s41467-023-
755 43384-y. PubMed PMID: 38097552; PMCID: PMC10721814.
- 756 29. Reeves DB, Gaebler C, Oliveira TY, Peluso MJ, Schiffer JT, Cohn LB, Deeks SG,
757 Nussenzweig MC. Impact of misclassified defective proviruses on HIV reservoir measurements.
758 *Nat Commun.* 2023;14(1):4186. Epub 20230713. doi: 10.1038/s41467-023-39837-z. PubMed
759 PMID: 37443365; PMCID: PMC10345136.

- 760 30. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y,
761 Rofail D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT,
762 Hamilton JD, Baum A, ..., Investigators T. REGN-COV2, a Neutralizing Antibody Cocktail, in
763 Outpatients with Covid-19. *N Engl J Med*. 2021;384(3):238-51. Epub 20201217. doi:
764 10.1056/NEJMoa2035002. PubMed PMID: 33332778; PMCID: PMC7781102.
- 765 31. Watson JA, Kissler SM, Day NPJ, Grad YH, White NJ. Characterizing SARS-CoV-2
766 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies. *Antimicrob*
767 *Agents Chemother*. 2022;66(7):e0019222. Epub 20220623. doi: 10.1128/aac.00192-22. PubMed
768 PMID: 35736134; PMCID: PMC9295592.
- 769 32. Standing JF, Buggiotti L, Guerra-Assuncao JA, Woodall M, Ellis S, Agyeman AA, Miller
770 C, Okechukwu M, Kirkpatrick E, Jacobs AI, Williams CA, Roy S, Martin-Bernal LM, Williams
771 R, Smith CM, Sanderson T, Ashford FB, Emmanuel B, Afzal ZM, ..., Group PV. Randomized
772 controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult
773 outpatients. *Nat Commun*. 2024;15(1):1652. Epub 20240223. doi: 10.1038/s41467-024-45641-0.
774 PubMed PMID: 38396069; PMCID: PMC10891158.
- 775 33. Lonsdale DO, Kipper K, Baker EH, Barker CIS, Oldfield I, Philips BJ, Johnston A,
776 Rhodes A, Sharland M, Standing JF. β -Lactam antimicrobial pharmacokinetics and target
777 attainment in critically ill patients aged 1 □day to 90 □years: the ABDose study. *J Antimicrob*
778 *Chemother*. 2020;75(12):3625-34. doi: 10.1093/jac/dkaa363. PubMed PMID: 32989452.
- 779 34. Singh S, Boyd S, Schilling WHK, Watson JA, Mukaka M, White NJ. The relationship
780 between viral clearance rates and disease progression in early symptomatic COVID-19: a
781 systematic review and meta-regression analysis. *J Antimicrob Chemother*. 2024. Epub 20240222.
782 doi: 10.1093/jac/dkae045. PubMed PMID: 38385479.
- 783 35. Prague M, Lavielle M. SAMBA: A novel method for fast automatic model building in
784 nonlinear mixed-effects models. *CPT Pharmacometrics Syst Pharmacol*. 2022;11(2):161-72.
785 Epub 20220201. doi: 10.1002/psp4.12742. PubMed PMID: 35104058; PMCID: PMC8846636.
- 786 36. Bing A, Hu Y, Prague M, Hill AL, Li JZ, Bosch RJ, De Gruttola V, Wang R. Comparison
787 of empirical and dynamic models for HIV viral load rebound after treatment interruption. *Stat*
788 *Commun Infect Dis*. 2020;12(Suppl 1). Epub 20200821. doi: 10.1515/scid-2019-0021. PubMed
789 PMID: 34158910; PMCID: PMC8216669.
- 790 37. Chan PL, Jacqmin P, Lavielle M, McFadyen L, Weatherley B. The use of the SAEM
791 algorithm in MONOLIX software for estimation of population pharmacokinetic-
792 pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. *J*
793 *Pharmacokinet Pharmacodyn*. 2011;38(1):41-61. Epub 2010/11/19. doi: 10.1007/s10928-010-
794 9175-z. PubMed PMID: 21088872; PMCID: PMC3020311.
- 795 38. Ke R, Zitzmann C, Ho DD, Ribeiro RM, Perelson AS. In vivo kinetics of SARS-CoV-2
796 infection and its relationship with a person's infectiousness. *Proc Natl Acad Sci U S A*.
797 2021;118(49). doi: 10.1073/pnas.2111477118. PubMed PMID: 34857628.
- 798 39. Galmiche S, Cortier T, Charmet T, Schaeffer L, Chény O, von Platen C, Lévy A, Martin
799 S, Omar F, David C, Mailles A, Carrat F, Cauchemez S, Fontanet A. SARS-CoV-2 incubation
800 period across variants of concern, individual factors, and circumstances of infection in France: a
801 case series analysis from the ComCor study. *Lancet Microbe*. 2023;4(6):e409-e17. Epub
802 20230418. doi: 10.1016/S2666-5247(23)00005-8. PubMed PMID: 37084751; PMCID:
803 PMC10112864.
- 804